AstraZeneca Feed

2025-10-19 08:35:27 AstraZeneca: Datroway demonstrated an unprecedented median OS improvement of five months vs. chemotherapy for patients with metastatic TNBC for whom immunotherapy was not an option in TROPION-Breast02

2025-10-18 16:35:44 AstraZeneca: Enhertu reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

2025-10-18 16:30:41 AstraZeneca: Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

2025-10-17 14:25:05 AstraZeneca: Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

2025-10-17 14:10:54 AstraZeneca: Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

2025-10-13 08:06:03 AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO 12724,00 SEK | -0,45% | 1 992 MSEK

2025-10-13 08:01:50 AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients 12724,00 SEK | -0,45% | 1 992 MSEK

2025-10-09 18:33:09 AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs 12782,00 SEK | -1,22% | 7 244 MSEK

2025-10-07 08:00:36 AstraZeneca: Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension 12780,00 SEK | +0,42% | 2 563 MSEK

2025-10-06 08:33:36 AstraZeneca: Datroway improved OS and PFS in TROPION-Breast02 12726,00 SEK | +0,60% | 4 571 MSEK

2025-09-29 08:30:33 AstraZeneca: Enhertu improved IDFS in early BC in DB-05 11088,00 SEK | +0,80% | 3 172 MSEK

2025-09-29 08:02:50 AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange 11088,00 SEK | +0,80% | 3 172 MSEK

2025-09-24 08:09:10 AstraZeneca: Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer 11210,00 SEK | -0,43% | 2 026 MSEK

2025-09-22 08:08:37 AstraZeneca: Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1 11500,00 SEK | +1,73% | 2 109 MSEK

2025-09-22 08:00:41 AstraZeneca: Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps 11500,00 SEK | +1,73% | 2 109 MSEK

2025-09-19 08:00:51 AstraZeneca: Alexion data presented at ECTRIMS 2025 reinforces Ultomiris leadership in transforming care for patients with NMOSD 11304,00 SEK | +0,50% | 6 295 MSEK

2025-09-17 08:06:45 AstraZeneca: Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis 11396,00 SEK | +0,44% | 2 018 MSEK

2025-09-17 08:02:38 AstraZeneca: Update on the RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease 11396,00 SEK | +0,44% | 2 018 MSEK

2025-09-07 08:16:18 AstraZeneca: Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

2025-08-30 16:16:28 AstraZeneca: Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial

2025-07-29 08:00:39 Resultat för AstraZeneca: första halvåret samt andra kvartalet 2025 11158,00 SEK | +3,41% | 8 318 MSEK

2025-07-28 08:03:28 AstraZeneca: Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers 10790,00 SEK | -0,11% | 8 029 MSEK

2025-07-25 12:50:55 AstraZeneca: Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential 10802,00 SEK | -0,95% | 9 523 MSEK

2025-07-24 08:05:25 AstraZeneca: Gefurulimab nanobody met Phase III endpoints 10906,00 SEK | +2,17% | 3 838 MSEK

2025-07-22 08:02:18 AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D 10352,00 SEK | +1,17% | 2 729 MSEK

2025-07-21 08:07:25 AstraZeneca: Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer 10232,00 SEK | -0,60% | 3 262 MSEK

2025-07-16 08:05:28 AstraZeneca: Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis 10436,00 SEK | -0,57% | 2 000 MSEK

2025-07-14 08:09:24 AstraZeneca: Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension 10662,00 SEK | +2,03% | 1 667 MSEK

2025-07-14 08:00:00 AstraZeneca: Baxdrostat met primary endpt in BaxHTN PhIII trial 10662,00 SEK | +2,03% | 1 667 MSEK

2025-07-04 08:03:37 AstraZeneca: Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer 10336,00 SEK | +1,29% | 1 239 MSEK

2025-06-24 08:01:49 AstraZeneca: Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer 10332,00 SEK | -0,84% | 5 548 MSEK

2025-06-24 08:00:00 AstraZeneca: Datroway approved in US for EGFRm lung cancer 10332,00 SEK | -0,84% | 5 548 MSEK

2025-06-23 08:04:44 AstraZeneca: Alexion data presented at EAN 2025 highlights its leadership and commitment to improving patient outcomes in rare neurological diseases 10420,00 SEK | +0,27% | 2 633 MSEK

2025-06-13 10:30:32 AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research 10986,00 SEK | -0,40% | 2 802 MSEK

2025-06-06 08:03:35 AstraZeneca: Fixed-duration -based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting 10782,00 SEK | +0,77% | 1 450 MSEK

2025-06-02 14:06:33 AstraZeneca: Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial 10574,00 SEK | -1,36% | 3 386 MSEK

2025-06-01 14:05:29 AstraZeneca: Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

2025-06-01 14:00:45 AstraZeneca: Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial

2025-05-27 08:01:09 AstraZeneca: Imfinzi recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for muscle-invasive bladder cancer 10484,00 SEK | +0,46% | 1 596 MSEK

2025-05-21 08:00:43 AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer 10492,00 SEK | +0,71% | 4 630 MSEK

2025-05-20 08:07:39 AstraZeneca: Acquisition of EsoBiotec completed 10418,00 SEK | +0,44% | 3 864 MSEK

2025-05-19 18:18:40 AstraZeneca: Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma 10418,00 SEK | +0,44% | 3 864 MSEK

2025-05-13 08:01:31 AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 10180,00 SEK | -0,90% | 2 027 MSEK

2025-05-12 08:05:09 AstraZeneca: Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential 10272,00 SEK | +0,31% | 3 949 MSEK

2025-05-09 08:00:33 AstraZeneca: Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial 10240,00 SEK | +1,05% | 3 796 MSEK

2025-05-07 08:30:35 AstraZeneca: Enhertu improved pCR in early-stage breast cancer 10504,00 SEK | -1,83% | 4 946 MSEK

2025-05-06 08:04:14 AstraZeneca: Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma 10700,00 SEK | -0,50% | 4 640 MSEK

2025-05-02 08:05:15 AstraZeneca: Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma 10754,00 SEK | +1,38% | 2 991 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

AstraZeneca

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden